These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25656048)

  • 1. Activating mutations of GNAS and KRAS in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas.
    Frampton AE; Stebbing J; Gall TM; Silver B; Jiao LR; Krell J
    Expert Rev Mol Diagn; 2015 Mar; 15(3):325-8. PubMed ID: 25656048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
    Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
    Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia.
    Singhi AD; McGrath K; Brand RE; Khalid A; Zeh HJ; Chennat JS; Fasanella KE; Papachristou GI; Slivka A; Bartlett DL; Dasyam AK; Hogg M; Lee KK; Marsh JW; Monaco SE; Ohori NP; Pingpank JF; Tsung A; Zureikat AH; Wald AI; Nikiforova MN
    Gut; 2018 Dec; 67(12):2131-2141. PubMed ID: 28970292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
    Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
    Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis.
    Tamura K; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Ideno N; Aso T; Miyazaki T; Ohuchida K; Takahata S; Ito T; Ushijima Y; Oda Y; Mizumoto K; Tanaka M
    Surgery; 2015 Feb; 157(2):277-84. PubMed ID: 25530484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.
    Wu J; Matthaei H; Maitra A; Dal Molin M; Wood LD; Eshleman JR; Goggins M; Canto MI; Schulick RD; Edil BH; Wolfgang CL; Klein AP; Diaz LA; Allen PJ; Schmidt CM; Kinzler KW; Papadopoulos N; Hruban RH; Vogelstein B
    Sci Transl Med; 2011 Jul; 3(92):92ra66. PubMed ID: 21775669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
    Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
    Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.
    Ohtsuka T; Tomosugi T; Kimura R; Nakamura S; Miyasaka Y; Nakata K; Mori Y; Morita M; Torata N; Shindo K; Ohuchida K; Nakamura M
    Surg Today; 2019 Nov; 49(11):887-893. PubMed ID: 30879148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
    Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs".
    Matthaei H; Wu J; Dal Molin M; Shi C; Perner S; Kristiansen G; Lingohr P; Kalff JC; Wolfgang CL; Kinzler KW; Vogelstein B; Maitra A; Hruban RH
    Am J Surg Pathol; 2014 Mar; 38(3):360-3. PubMed ID: 24525507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
    Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
    J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of EUS-acquired pancreatic cyst fluid for KRAS and GNAS mutations for diagnosis of intraductal papillary mucinous neoplasia and mucinous cystic lesions: a systematic review and meta-analysis.
    McCarty TR; Paleti S; Rustagi T
    Gastrointest Endosc; 2021 May; 93(5):1019-1033.e5. PubMed ID: 33359054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
    Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
    Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.
    Schmitz D; Kazdal D; Allgäuer M; Trunk M; Vornhusen S; Nahm AM; Doll M; Weingärtner S; Endris V; Penzel R; Kirchner M; Brandt R; Neumann O; Sültmann H; Budczies J; Kienle P; Magdeburg R; Hetjens S; Schirmacher P; Bergmann F; Rudi J; Stenzinger A; Volckmar AL
    Genes Chromosomes Cancer; 2021 Jul; 60(7):489-497. PubMed ID: 33686791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms.
    Gaujoux S; Parvanescu A; Cesaretti M; Silve C; Bieche I; Rebours V; Lévy P; Sauvanet A; Cros J
    Ann Surg Oncol; 2019 Aug; 26(8):2640-2650. PubMed ID: 31025231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
    Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
    Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts.
    Kanda M; Knight S; Topazian M; Syngal S; Farrell J; Lee J; Kamel I; Lennon AM; Borges M; Young A; Fujiwara S; Seike J; Eshleman J; Hruban RH; Canto MI; Goggins M
    Gut; 2013 Jul; 62(7):1024-33. PubMed ID: 22859495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational Mosaics of Cell-Free DNA from Pancreatic Cyst Fluids.
    Paziewska A; Polkowski M; Goryca K; Karczmarski J; Wiechowska-Kozlowska A; Dabrowska M; Mikula M; Ostrowski J
    Dig Dis Sci; 2020 Aug; 65(8):2294-2301. PubMed ID: 31925676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.